Screener
Kailera Therapeutics KLRA Total Operating Expenses
Total Operating Expenses at other companies
Other financials
Where this comes from
Reported directly by Kailera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Kailera Therapeutics’s 10-Q, filed May 26, 2026.
- Filed
- May 26, 2026, 4:29 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-239417
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses | ||
| Research and development | $70,873 | $10,130 |
| General and administrative | 13,787 | 10,328 |
| Total operating expenses | 84,660 | 20,458 |
| Loss from operations | (84,660) | (20,458) |
| Other income | ||
| Interest income | 5,716 | 1,675 |
| Other income, net | 79 | 800 |
Item 1. Financial Statements.
FAQ
- What is Kailera Therapeutics's total operating expenses?
- Kailera Therapeutics (KLRA) reported total operating expenses of $84.66M in Q1 2026.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.
Ask your AI about Kailera Therapeutics's total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude